Efficacy and Safety of Autologous Humanized CD19 CAR-T Therapy in R/R B-NHL

Overview

This clinical trial evaluated autologous humanized CD19 CAR-T (hCART19) therapy in 26 patients with relapsed or refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). The study demonstrated promising efficacy with manageable safety profiles over a median follow-up of 20.3 months.

Background

Relapsed or refractory B-cell non-Hodgkin lymphoma remains challenging despite advances in chemotherapy, targeted therapies, and hematopoietic stem cell transplantation. CAR-T cell therapy targeting CD19 has shown significant remission rates in B-cell malignancies but is limited by relapse and toxicities such as cytokine release syndrome. Humanization of the CAR single-chain variable fragment (scFv) aims to reduce immunogenicity and improve persistence and safety. While humanized CAR-T cells have shown efficacy in B-ALL, their performance in R/R B-NHL requires further evaluation.

Data Highlights

Key Findings

• Humanized CD19 CAR-T cells were successfully manufactured and infused in 26 patients with R/R B-NHL.
• The therapy showed encouraging efficacy with objective response rates consistent with or exceeding historical data for murine CAR-T cells.
• Adverse events including cytokine release syndrome and neurotoxicity were monitored and graded per ASTCT guidelines, with manageable safety profiles observed.
• Humanized scFv CAR-T cells potentially reduced immunogenicity risks associated with murine-derived CAR constructs.
• Persistence and expansion of CAR-T cells were assessed by flow cytometry, demonstrating in vivo activity and B-cell aplasia as a pharmacodynamic marker.
• Statistical analyses included Kaplan-Meier survival estimates and Cox regression to identify prognostic factors influencing outcomes.

Clinical Implications

Humanized CD19 CAR-T therapy represents a promising treatment option for patients with R/R B-NHL, potentially offering improved safety and sustained efficacy compared to murine-based CAR-T products. Clinicians should consider monitoring for CRS and neurotoxicity using standardized grading systems and assess CAR-T cell kinetics to guide patient management. Further studies are warranted to confirm long-term benefits and optimize patient selection.

Conclusion

Autologous humanized CD19 CAR-T cell therapy demonstrates favorable efficacy and safety in patients with relapsed or refractory B-cell non-Hodgkin lymphoma, supporting its potential as a valuable therapeutic approach in this difficult-to-treat population.

References

1. FDA Approved CAR-T Products -- CD19 Targeted Therapies
2. ASTCT 2019 Guidelines -- CRS and ICANS Grading
3. Lugano Classification 2014 -- Response Assessment in Lymphoma
4. NCT04532268 -- Clinical Trial of hCART19 in R/R B-NHL